Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Learn how MSK uses TIL therapy for melanoma – the first immunotherapy approved by the FDA to treat a solid tumor.
Monotherapy with the oral KRAS G12C inhibitor glecirasib demonstrated efficacy in previously treated patients with KRAS G12C–mutated NSCLC, according to data presented during the ASCO…
Our Ductal Carcinoma in Situ (DCIS) Program aims to provide comprehensive support services, resources, and education from diagnosis through long term survivorship.
In this study, Rubinson, Tanaka, and colleagues reveal that a subset of switch-II pocket-binding KRASG12C inhibitors can target all RASG12C proteins. In contrast to KRASG12C-specific…
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on…
Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.